|
|
|
LifeScienceHistory.com - Check us out on Instagram
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Adamis Pharmaceuticals Corp.
| | | Phone: | (858) 997-2400 | Year Established: | 2006 | Ticker: | ADMP | Exchange: | NASDAQ | Main Contact: | David J. Marguglio, Senior VP, Corporate Development | | Other Contacts: | Karen K. Daniels, VP, Operations Thomas Moll, Ph.D., VP, Research Robert O. Hopkins, VP, CFO Dennis J. Carlo, Ph.D., President & CEO
| | Company Description | Adamis Pharmaceuticals is a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. The company’s current specialty pharmaceutical product candidates include the Epinephrine Injection PFS syringe product for use in the emergency treatment of anaphylaxis, APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease, and APC-3000, an HFA inhaled nasal steroid product for the treatment of allergic rhinitis. The company's vaccine product candidates and cancer drug product candidates under research and development include TeloB-VAX, a cell-based therapeutic cancer vaccine and three drugs, APC-100, APC-200, and APC-300, for the treatment of prostate cancer. | |
|
|
|
|
|